We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas (EPL)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00779337
First Posted: October 24, 2008
Last Update Posted: May 22, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
The Atlantic Philanthropies
Australian Department of Industry, Tourism and Resources
British Society for Haematology
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Maher Gandhi, Queensland Institute of Medical Research
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)